Priscilla K. Brastianos, MD | Authors


Palbociclib Shows Promise for Treatment of Brain Metastases Harboring CDK Alterations

November 24, 2019

An interim analysis of the phase II study of palbociclib for the treatment of patients with brain metastases harboring CDK alterations was presented at the 2019 Society for NeuroOncology Annual Meeting by Priscilla K. Brastianos, MD, director of the central nervous system brain metastasis program, Massachusetts General Hospital.